IFP Advisors
SABS icon

IFP Advisors’s SAB Biotherapeutics SABS Stock Holding History

IFP Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$81.5K Sell
25,705
-12,994
-34% -$47.3K ﹤0.01% 2093
2026
Q2 		$151K Buy
+38,699
New +$144K ﹤0.01% 1704

Other funds holding SABS

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Kestra Advisory Services
Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return
First PREMIER Bank
First PREMIER Bank Sioux Falls, South Dakota $621M AUM 13.03% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Plante Moran Financial Advisors
Plante Moran Financial Advisors Southfield, Michigan $2.2B AUM 13.29% 1-Year Est. Return

IFP Advisors's SABS Position: Q3 2026 in Review

IFP Advisors reduced its SAB Biotherapeutics (SABS) stake by 34% in Q3 2026, selling an estimated $47.3K and leaving 25,705 shares worth $81.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

IFP Advisors first reported a position in SABS in Q2 2026 and has held it in 2 quarters since. The position peaked at $151K in Q2 2026. 19 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • IFP Advisors held 25,705 shares of SAB Biotherapeutics worth $81.5K as of Q3 2026.
  • IFP Advisors sold 12,994 SAB Biotherapeutics shares in Q3 2026, an estimated $47.3K.
  • SAB Biotherapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #2093 holding.
  • IFP Advisors first reported a position in SAB Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • IFP Advisors's SAB Biotherapeutics position peaked at $151K in Q2 2026.
  • 19 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.